Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 35 - Antineoplastic agents
Patents for A61P 35 - Antineoplastic agents (221,099)
10/2013
10/01/2013US8545843 Treatment of vasculitis
10/01/2013US8545838 Compositions and methods for cancer immunotherapy
10/01/2013US8545835 Human prostate cell lines in cancer treatment
10/01/2013US8545550 Drug-delivery endovascular stent and method for treating restenosis
10/01/2013CA2735844C Use of piperine and analogues thereof in the prevention of skin cancer
10/01/2013CA2732950C Imidazopyridin-2-one derivatives
10/01/2013CA2730715C Antineoplastic combinations of 4-anilino-3-cyanoquinolines and capecitabine
10/01/2013CA2673924C Liposomal pharmaceutical preparation and method for manufacturing the same
10/01/2013CA2672155C Use of xanthohumol or isoxanthohumol as an active substance for the prevention and/or control of liver diseases
10/01/2013CA2644143C Combinations comprising bcr-abl/c-kit/pdgf-r tk inhibitors for treating cancer
10/01/2013CA2605738C Novel azaheterocyclic compounds as kinase inhibitors
10/01/2013CA2594508C Cyanoguanidine compounds
10/01/2013CA2594482C Antitumor agent
10/01/2013CA2582668C Nanoparticles comprising antigens and adjuvants, and immunogenic structures
10/01/2013CA2579279C Tricyclic thiazole derivatives as pi3 kinases
10/01/2013CA2565568C Pyrimidines as plk inhibitors
10/01/2013CA2481515C Anti-her2 antibody variants
10/01/2013CA2479835C An ephrin-b receptor protein involved in carcinoma
10/01/2013CA2433862C Molecular antigen array presenting amyloid beta
10/01/2013CA2418531C Therapeutic methods for treating subjects with a recombinant erythropoietin having high activity and reduced side effects
10/01/2013CA2239448C Blockade of t lymphocyte down-regulation associated with ctla-4 signaling
09/2013
09/27/2013CA2784240A1 Stable bortezomib formulations
09/26/2013WO2013142427A1 Compounds and methods for kinase modulation, and indications therefor
09/26/2013WO2013142382A1 Substituted pyridopyrimidine compounds and their use as flt3 inhibitors
09/26/2013WO2013142376A1 Composition and methods for cell modulation
09/26/2013WO2013142307A1 Carbamate compounds and of making and using same
09/26/2013WO2013142281A1 Inhibition of mcl-1 and/or bfl-1/a1
09/26/2013WO2013142266A1 Estrogen receptor modulators and uses thereof
09/26/2013WO2013142261A1 Hedgehog pathway inhibition for cartilage tumor and metachondromatosis treatment
09/26/2013WO2013142255A2 Multi-specific binding agents
09/26/2013WO2013141586A1 Novelpyridopyrimidine derivatives and use thereof
09/26/2013WO2013141346A1 Method for producing liposome encapsulating paclitaxel monoglycoside and/or docetaxel monoglycoside
09/26/2013WO2013141264A1 Novel cysteine compound and salt thereof
09/26/2013WO2013141092A1 Cancer metastasis marker and method for diagnosing cancer metastasis using same
09/26/2013WO2013140389A1 Plif multimeric peptides and uses thereof
09/26/2013WO2013140319A1 Crystalline form of a succinate salt
09/26/2013WO2013140148A1 Quinazoline compounds and their use in therapy
09/26/2013WO2013139991A1 Pharmaceutical formulation comprising bendamustine
09/26/2013WO2013139918A1 Topical application of ingenol mebutate with occlusion
09/26/2013WO2013139906A1 Medicament for the treatment of acute myeloid leukemia (aml)
09/26/2013WO2013139734A1 Use of (rs)-s-cyclopropyl-s-(4-{[4-{[1r, 2r)-2-hydroxy-1-methylpropyl]oxy}-5-(trifluoromethyl)pyrimidin-2-yl]amino}phenyl)sulfoximide for treating specific tumours
09/26/2013WO2013139724A1 Combination therapy (vemrufenib and a mdm2 inhibitor) for the treatment proliferative disorders
09/26/2013WO2013139687A1 Method for administration of an anti tumor agent
09/26/2013WO2013139423A1 Combination of a 6-oxo-1,6-dihydro-pyridazine derivative having anti-cancer activity with other anti-tumor compounds
09/26/2013WO2013139300A1 Recombinant lentiviral vector formulation
09/26/2013WO2013138863A1 Kinase inhibitors for the treatment of cancer
09/26/2013WO2013090732A3 Collateral gene inactivation biomarkers and targets for cancer therapy
09/26/2013WO2013072390A3 Stilbene compounds as ppar beta/delta inhibitors for treating ppar beta/delta transmitted illnesses
09/26/2013WO2012159565A9 6-(aryl-carboxamide) imidazo [1,2-a] pyrimidine and 6-(aryl carboxamide) [1,2,4] triazolo [4,3-a] pyrimidine as hedgehog pathway inhibitor and use thereof
09/26/2013WO2012121423A8 Pharmaceutical composition for preventing and treating complications of diabetes containing a traditional oriental medicine extract or a fraction thereof as an active ingredient
09/26/2013US20130253000 Treatment of solid tumors with rapamycin derivatives
09/26/2013US20130252998 Cci-779 formulations for parenteral administration
09/26/2013US20130252325 Duplexed Parvovirus Vectors
09/26/2013CA2861056A1 Combination therapy (vemrufenib and a mdm2 inhibitor) for the treatment proliferative disorders
09/25/2013EP2641919A2 Antigen-binding constructs
09/25/2013EP2641618A2 Humanized anti-CD79B antibodies and immunoconjugates and methods of use
09/25/2013EP2641612A1 Alpha 5 - beta 1 antibodies and their uses
09/25/2013EP2641611A2 Combination therapy
09/25/2013EP2641610A2 Anticancer composition containing gkn 1
09/25/2013EP2641605A1 Novel polymer derivative of cytidine metabolism antagonist
09/25/2013EP2641601A1 Methods of treating multiple myeloma using combination therapies based on HuLuc63 with bortezimob
09/25/2013EP2641600A1 Methods of Treating Multiple Myeloma Using Combination Therapies based on Anti-CS1 Antibodies
09/25/2013EP2641599A1 Composition of an oral dosage form of vitamin E esters combination with enhanced antioxidant activity.
09/25/2013EP2641592A1 Pharmaceutical formulation comprising bendamustine
09/25/2013EP2641590A1 Pharmaceutical compositions comprising imidazoquinolin(amines) and derivatives thereof suitable for local administration
09/25/2013EP2640716A1 Cyclic amide compounds and their use in the treatment of disease
09/25/2013EP2640715A1 Quinoline derivatives as pik3 inhibitors
09/25/2013EP2640704A1 Nampt inhibitors
09/25/2013EP2640702A1 3-(aminoaryl)-pyridine compounds
09/25/2013EP2640698A1 Nampt and rock inhibitors
09/25/2013EP2640468A1 Method of administration and treatment
09/25/2013EP2640467A1 Crystalline form of an inhibitor of mdm2/4 and p53 interaction
09/25/2013EP2640424A1 Novel conjugates for targeted drug delivery
09/25/2013EP2640422A1 Polymeric conjugates of active principles, their process of preparation and their polymeric intermediates
09/25/2013EP2640412A1 Use of prolactin receptor antagonist and chemotherapeutic drug for treating ovarian cancer
09/25/2013EP2640406A1 Treatment of cancer with elevated dosages of soluble fgfr1 fusion proteins
09/25/2013EP2640399A2 Methods and compositions for modulating pd1
09/25/2013EP2640392A2 Substituted 4-(selenophen-2(or 3)-ylamino)pyrimidine compounds and methods of use thereof
09/25/2013EP2640390A2 Methods of treating cancer
09/25/2013EP2640387A1 Method of treatment with braf inhibitor
09/25/2013EP2640386A1 Combination of checkpoint kinase 1 inhibitors and wee 1 kinase inhibitors
09/25/2013EP2640385A1 Preselection of subjects for therapeutic treatment based on hypoxic status
09/25/2013EP2640384A1 Preselection of subjects for therapeutic treatment with oxygen sensitive agents based on hypoxic status
09/25/2013EP2640383A1 Method for treating breast cancer and ovarian cancer
09/25/2013EP2640381A2 Cannabinoid receptor antagonists-inverse agonists useful for treating metabolic disorders, including obesity and diabetes
09/25/2013EP2640380A1 Pharmaceutical combination of paclitaxel and a cdk inhibitor
09/25/2013EP2640377A1 Fgfr1 extracellular domain combination therapies
09/25/2013EP2640372A1 Preselection of subjects for therapeutic treatment with elesclomol based on hypoxic status
09/25/2013EP2640369A1 Methods of treating tumors
09/25/2013EP2640367A2 Benzoxazepines as inhibitors of pi3k/mtor and methods of their use and manufacture
09/25/2013EP2640366A2 Benzoxazepines as inhibitors of pi3k/mtor and methods of their use and manufacture
09/25/2013EP2520589A9 Anti-cd27 antibody
09/25/2013CN103328648A Peptide with safer secondary structure, peptide library, and production methods for same
09/25/2013CN103328633A Nucleic acid molecules inducing RNA interference, and uses thereof
09/25/2013CN103328626A Cancer stem cell mass and process for production thereof
09/25/2013CN103328514A Protein complexes for antigen binding and methods of use
09/25/2013CN103328513A Anti CCR4 antibodies and uses thereof
09/25/2013CN103328496A Cancer-targeting peptides and uses thereof in cancer treatment and diagnosis
09/25/2013CN103328494A Novel derivatives of oxazaphosphorines that are pre-activated, use and method of preparation
09/25/2013CN103328479A 7-hydroxy-pyrazolo[1,5-A] pyrimidine compounds and their use as CCR2 receptor antagonists
1 ... 130 131 132 133 134 135 136 137 138 139 140 141 142 143 144 145 146 147 148 149 150 ... 2211